News & Events about Pds Biotechnology Corp.
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced its participation in the Channelchek Takeaway Series...
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will participate in a fireside ...
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune platform PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at 8:00 AM EST FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq...
Thinking about buying stock in Lucid Group, Elys Game Technology, Gaotu Techedu, PDS Biotechnology, or Southwest Airlines? Thinking about buying stock in Lucid Group, Elys Game Technology, Gaotu Techedu, PDS Biotechnology, or Southwest Airlines? PR Newswire NEW YORK, Dec. 28, 2022 NEW YORK, Dec...
Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2 clinical trial of PDS0101 triple combinationFLORHAM PARK, N.J., Dec. 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage ...